Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

IMVT

Phase 3

Batoclimab (IMVT-1401)

Thyroid Eye Disease (TED)

H2 2025

Initiated two Ph3 trials in Q3 2022. 2/6/25- Topline data in H2 2025.

Data readout

PBYI

Phase 2

Alisertib

Extensive-stage small cell lung cancer (SCLC)

2025

Suspected Mover: ALISCA-Lung1 trial. 2/13/24- Initiated Ph2 trial. 12/24- Additional interim data in 2025.

Data readout

MRSN

Phase 1

XMT-2056 (HER2 ADC)

Solid tumors (HER2-Expressing)

2025

3/27/24 Restarting Ph1 following lift of clinical hold. 8/13/24- Ongoing subject enrollment for DE portion. 3/3/25- Present initial data in 2025.

Data readout

ACIU

Phase 1

ACI-19626 (TDP-43-PET tracer)

Genetic frontotemporal dementia (FTD)

December 2025

01/25- Trial initiated w/ interim data in December 2025.

Data Readout

KURA

Phase 1

KO-2806 + cabozantinib

Solid tumors, clear cell renal cell carcinoma (ccRCC)

H2 2025

FIT-001 trial (ccRCC cohort) 3/6/24- First patient dosed. Dose esc. as monotherapy continues. 2/28/25- Prelim data in H2 2025.

Data readout

NRIX

Phase 1

NX-1607

Solid tumors

2025

3/20/24- Presentation at ACS meeting '24. 1/13/25- Establish Ph1b monotherapy dose and share additional data in 2025.

Data readout

CORT

Phase 4

Korlym® (Relacorilant)

Hypercortisolism (Cushing Syndrome)

2025

CATALYST trial. 6/24/24- Prevalence phase results presented at ADA '24. 12/12/24- Reported trial data. Complete results will be presented at a medical conference in 2025.

Data readout

FDMT

Phase 1/2

4D-710

Cystic Fibrosis

H2 2025

AEROW trial. 01/23/24- Received FDA pediatric disease desig. 9/23/24- Preclinical data on 9/27 at NACFC '24. 2/28/25- Interim data at a scientific conference in H2 2025.

Data readout

INO

Phase 1

DNA-Encoded Monoclonal Antibodies (DMAbs)

COVID-19

2025

3/14/25- Announced promising interim results from Ph1 PoC trial. 3/18/25- Study ongoing and present/publish interim data in 2025.

Data readout

RXRX

Phase 2

REC-3964

Clostridium difficile Colitis

YE 2025

11/6/24- Dosed first patient w/ prelim readout by YE 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20